Iovance Biotherapeutics stock rose over 5% due to positive analyst recommendation

From Nasdaq: 2025-01-02 19:03:00

Stocks of Iovance Biotherapeutics (NASDAQ: IOVA) rose over 5% following a positive analyst recommendation from Stifel. Analyst Benjamin Burnett named Iovance as the top stock pick in the biotech sector for 2025, citing the popularity of its cancer drug Amtagvi. Burnett also highlighted the potential growth of another Iovance drug, Proleukin, in the second half of the year. With limited competition in the cancer drug market, Iovance is positioned for continued success.

For investors seeking second chances, analysts are issuing “Double Down” stock recommendations for companies with significant growth potential. Past recommendations for Nvidia, Apple, and Netflix have yielded substantial returns. The latest alerts highlight three companies with promising opportunities for growth.



Read more at Nasdaq: Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today